KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBIT Margin: 2009-2025

Historic EBIT Margin for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to 5.11%.

  • Jazz Pharmaceuticals' EBIT Margin fell 1956.00% to 5.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.86%, marking a year-over-year decrease of 538.00%. This contributed to the annual value of 17.61% for FY2024, which is 252.00% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' EBIT Margin stood at 5.11%, which was up 182.04% from -6.23% recorded in Q2 2025.
  • Jazz Pharmaceuticals' EBIT Margin's 5-year high stood at 26.68% during Q1 2021, with a 5-year trough of -27.09% in Q4 2022.
  • In the last 3 years, Jazz Pharmaceuticals' EBIT Margin had a median value of 15.29% in 2023 and averaged 12.83%.
  • Examining YoY changes over the last 5 years, Jazz Pharmaceuticals' EBIT Margin showed a top increase of 6,215bps in 2021 and a maximum decrease of 4,448bps in 2021.
  • Jazz Pharmaceuticals' EBIT Margin (Quarterly) stood at 5.51% in 2021, then tumbled by 3,260bps to -27.09% in 2022, then surged by 3,920bps to 12.11% in 2023, then spiked by 543bps to 17.53% in 2024, then plummeted by 1,956bps to 5.11% in 2025.
  • Its EBIT Margin stands at 5.11% for Q3 2025, versus -6.23% for Q2 2025 and 17.53% for Q4 2024.